Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors.

Published in: JCO oncology practice (2024)

Mid-PRRT assessment predicts subsequent PRRT response in patients with WD-NET, especially those with PNET, informing personalized management and consideration of reduced bone marrow radiation exposure in high-risk patients.

Keyphrases

neuroendocrine tumors
bone marrow
end stage renal disease
newly diagnosed
ejection fraction
mesenchymal stem cells
prognostic factors